Ipilimumab

我们是谁

  • 1 月 9, 2024
    Efficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer ( NIPISAFE )
  • 1 月 19, 2023
    Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer
  • 4 月 5, 2022
    A Study of a Personalized Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
  • 4 月 5, 2022
    BMS-986253与Nivolumab或Nivolumab加Ipilimumab联合治疗晚期癌症的研究
  • 4 月 5, 2022
    The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
  • 4 月 5, 2022
    Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
  • 4 月 5, 2022
    Adoptive Cell Therapy Across Cancer Diagnoses
  • 4 月 5, 2022
    重组白细胞介素-15 与检查点抑制剂 Nivolumab 和 Ipilimumab 联合治疗难治性癌症患者
  • 4 月 5, 2022
    Nivolumab 和 Ipilimumab 以及放疗治疗 MSS 和 MSI 高的结直肠癌和胰腺癌
  • 4 月 5, 2022
    Ipilimumab, Maraviroc and Nivolumab (LUMINESCENCE)